BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31306217)

  • 1. Cerebrospinal Fluid Concentrations of Nimodipine Correlate With Long-term Outcome in Aneurysmal Subarachnoid Hemorrhage: Pilot Study.
    Riva R; Pegoli M; Contin M; Perrone A; Mohamed S; Zanello M
    Clin Neuropharmacol; 2019; 42(5):157-162. PubMed ID: 31306217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometry-based method for quantification of nimodipine and glutamate in cerebrospinal fluid. Pilot study with patients after aneurysmal subarachnoid haemorrhage.
    Mindt S; Tokhi U; Hedtke M; Groß HJ; Hänggi D
    J Clin Pharm Ther; 2020 Feb; 45(1):81-87. PubMed ID: 31421063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study.
    Schmid-Elsaesser R; Kunz M; Zausinger S; Prueckner S; Briegel J; Steiger HJ
    Neurosurgery; 2006 Jun; 58(6):1054-65; discussion 1054-65. PubMed ID: 16723884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous intra-arterial nimodipine infusion in patients with severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a feasibility study and outcome results.
    Bele S; Proescholdt MA; Hochreiter A; Schuierer G; Scheitzach J; Wendl C; Kieninger M; Schneiker A; Bründl E; Schödel P; Schebesch KM; Brawanski A
    Acta Neurochir (Wien); 2015 Dec; 157(12):2041-50. PubMed ID: 26439105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha1-acid glycoprotein concentrations and cerebrospinal fluid drug distribution after subarachnoid hemorrhage.
    Woodward DK; Hatton J; Ensom MH; Young B; Dempsey R; Clifton GD
    Pharmacotherapy; 1998; 18(5):1062-8. PubMed ID: 9758316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study.
    Ehlert A; Schmidt C; Wölfer J; Manthei G; Jacobs AH; Brüning R; Heindel W; Ringelstein EB; Stummer W; Pluta RM; Hesselmann V
    J Neurosurg; 2016 Jan; 124(1):51-8. PubMed ID: 26162034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage.
    Kieninger M; Gruber M; Knott I; Dettmer K; Oefner PJ; Bele S; Wendl C; Tuemmler S; Graf B; Eissnert C
    Neurocrit Care; 2019 Aug; 31(1):32-39. PubMed ID: 30725331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early matrix metalloproteinase-9 concentration in the first 48 h after aneurysmal subarachnoid haemorrhage predicts delayed cerebral ischaemia: An observational study.
    Triglia T; Mezzapesa A; Martin JC; Verdier M; Lagier D; Dufour H; Bruder N; Alessi MC; Velly LJ
    Eur J Anaesthesiol; 2016 Sep; 33(9):662-9. PubMed ID: 27355865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Course and Monitoring Parameters After Continuous Interventional Intra-Arterial Treatment in Patients with Refractory Cerebral Vasospasm.
    von der Brelie C; Doukas A; Stopfer A; Larsen N; Mehdorn M; Synowitz M; Jansen O
    World Neurosurg; 2017 Apr; 100():504-513. PubMed ID: 28131927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of invasive cerebral vasospasm treatment in patients with spontaneous subarachnoid hemorrhage and delayed cerebral ischemia-continuous selective intracarotid nimodipine therapy in awake patients without sedation.
    Paľa A; Schneider M; Brand C; Pedro MT; Özpeynirci Y; Schmitz B; Wirtz CR; Kapapa T; König R; Braun M
    Neurosurg Rev; 2019 Jun; 42(2):463-469. PubMed ID: 29804157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term, Continuous Intra-Arterial Nimodipine Treatment of Severe Vasospasm After Aneurysmal Subarachnoid Hemorrhage.
    Hockel K; Diedler J; Steiner J; Birkenhauer U; Danz S; Ernemann U; Schuhmann MU
    World Neurosurg; 2016 Apr; 88():104-112. PubMed ID: 26732964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)].
    Hänggi D; Etminan N; Mayer SA; Aldrich EF; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Macdonald RL;
    Neurocrit Care; 2019 Feb; 30(1):88-97. PubMed ID: 30014184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Nimodipine Administration through Feeding Tube on Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage.
    Isse FA; Abdallah YEH; Mahmoud SH
    J Pharm Pharm Sci; 2020; 23(1):100-108. PubMed ID: 32348716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Site-Specific, Sustained-Release Drug Delivery System for Aneurysmal Subarachnoid Hemorrhage.
    Hänggi D; Etminan N; Steiger HJ; Johnson M; Peet MM; Tice T; Burton K; Hudson B; Turner M; Stella A; Heshmati P; Davis C; Faleck HJ; Macdonald RL
    Neurotherapeutics; 2016 Apr; 13(2):439-49. PubMed ID: 26935204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and Cerebral Concentration of Nimodipine During Established and Experimental Vasospasm Treatment.
    Albanna W; Weiss M; Conzen C; Clusmann H; Schneider T; Reinsch M; Müller M; Wiesmann M; Höllig A; Schubert GA
    World Neurosurg; 2017 Jun; 102():459-465. PubMed ID: 28344178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NEWTON-2 Cisternal (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage): A Phase 2, Multicenter, Randomized, Open-Label Safety Study of Intracisternal EG-1962 in Aneurysmal Subarachnoid Hemorrhage.
    Macdonald RL; Hänggi D; Ko NU; Darsaut TE; Carlson AP; Wong GK; Etminan N; Mayer SA; Aldrich EF; Diringer MN; Ng D; Strange P; Bleck T; Grubb R; Suarez JI
    Neurosurgery; 2020 Dec; 88(1):E13-E26. PubMed ID: 32985652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEWTON: Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage.
    Hänggi D; Etminan N; Macdonald RL; Steiger HJ; Mayer SA; Aldrich F; Diringer MN; Hoh BL; Mocco J; Strange P; Faleck HJ; Miller M
    Neurocrit Care; 2015 Oct; 23(2):274-84. PubMed ID: 25678453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage.
    Carlson AP; Hänggi D; Wong GK; Etminan N; Mayer SA; Aldrich F; Diringer MN; Schmutzhard E; Faleck HJ; Ng D; Saville BR; Bleck T; Grubb R; Miller M; Suarez JI; Proskin HM; Macdonald RL;
    Stroke; 2020 Apr; 51(4):1142-1149. PubMed ID: 32138631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Intra-Arterial and Intravenous Nimodipine Therapy of Cerebral Vasospasm After Subarachnoid Hemorrhage on Cerebrovascular Reactivity and Oxygenation.
    Hockel K; Diedler J; Steiner J; Birkenhauer U; Ernemann U; Schuhmann MU
    World Neurosurg; 2017 May; 101():372-378. PubMed ID: 28232152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher dose intra-arterial milrinone and intra-arterial combined milrinone-nimodipine infusion as a rescue therapy for refractory cerebral vasospasm.
    Duman E; Karakoç F; Pinar HU; Dogan R; Fırat A; Yıldırım E
    Interv Neuroradiol; 2017 Dec; 23(6):636-643. PubMed ID: 28956512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.